These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 7517720)

  • 21. Analysis of folylpoly-gamma-glutamate synthetase gene expression in human B-precursor ALL and T-lineage ALL cells.
    Leclerc GJ; Leclerc GM; Kinser TT; Barredo JC
    BMC Cancer; 2006 May; 6():132. PubMed ID: 16707018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of methotrexate resistance in acute leukemia. Decreased transport and polyglutamylation.
    Gorlick R; Cole P; Banerjee D; Longo G; Li WW; Hochhauser D; Bertino JR
    Adv Exp Med Biol; 1999; 457():543-50. PubMed ID: 10500832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Methotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.
    Wojtuszkiewicz A; Peters GJ; van Woerden NL; Dubbelman B; Escherich G; Schmiegelow K; Sonneveld E; Pieters R; van de Ven PM; Jansen G; Assaraf YG; Kaspers GJ; Cloos J
    J Hematol Oncol; 2015 May; 8():61. PubMed ID: 26022503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.
    Stark M; Wichman C; Avivi I; Assaraf YG
    Blood; 2009 Apr; 113(18):4362-9. PubMed ID: 19131550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate.
    Masson E; Relling MV; Synold TW; Liu Q; Schuetz JD; Sandlund JT; Pui CH; Evans WE
    J Clin Invest; 1996 Jan; 97(1):73-80. PubMed ID: 8550853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
    Tulstrup M; Moriyama T; Jiang C; Grosjean M; Nersting J; Abrahamsson J; Grell K; Hjalgrim LL; Jónsson ÓG; Kanerva J; Lund B; Nielsen SN; Nielsen RL; Overgaard U; Quist-Paulsen P; Pruunsild K; Vaitkeviciene G; Wolthers BO; Zhang H; Gupta R; Yang JJ; Schmiegelow K
    Blood; 2020 Sep; 136(10):1161-1168. PubMed ID: 32391884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.
    Dervieux T; Brenner TL; Hon YY; Zhou Y; Hancock ML; Sandlund JT; Rivera GK; Ribeiro RC; Boyett JM; Pui CH; Relling MV; Evans WE
    Blood; 2002 Aug; 100(4):1240-7. PubMed ID: 12149204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
    Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
    Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disparate affinities of antifolates for folylpolyglutamate synthetase from human leukemia cells.
    Longo GS; Gorlick R; Tong WP; Ercikan E; Bertino JR
    Blood; 1997 Aug; 90(3):1241-5. PubMed ID: 9242558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists.
    Clarke L; Waxman DJ
    Arch Biochem Biophys; 1987 Aug; 256(2):585-96. PubMed ID: 3619447
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.
    Kager L; Cheok M; Yang W; Zaza G; Cheng Q; Panetta JC; Pui CH; Downing JR; Relling MV; Evans WE
    J Clin Invest; 2005 Jan; 115(1):110-7. PubMed ID: 15630450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.
    Cheng Q; Wu B; Kager L; Panetta JC; Zheng J; Pui CH; Relling MV; Evans WE
    Pharmacogenetics; 2004 Aug; 14(8):557-67. PubMed ID: 15284538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro.
    Hum MC; Smith AK; Lark RH; Winick NJ; Kamen BA
    Pharmacotherapy; 1997; 17(6):1260-6. PubMed ID: 9399609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Folylpolyglutamate synthase is a major determinant of intracellular methotrexate polyglutamates in patients with rheumatoid arthritis.
    Yamamoto T; Shikano K; Nanki T; Kawai S
    Sci Rep; 2016 Oct; 6():35615. PubMed ID: 27752107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
    McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
    Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Folate analog nonsubstrates and inhibitors of folylpolyglutamate synthetase as potential cancer chemotherapy drugs.
    McGuire JJ; Piper JR; Coward JK; Galivan J
    NCI Monogr; 1987; (5):139-44. PubMed ID: 2448652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
    Panetta JC; Wall A; Pui CH; Relling MV; Evans WE
    Clin Cancer Res; 2002 Jul; 8(7):2423-9. PubMed ID: 12114448
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular pharmacokinetic of methotrexate and its modulation by folylpolyglutamate synthetase and γ-glutamyl hydrolase in tumor cells.
    Tang F; Zou L; Chen J; Meng F
    PLoS One; 2024; 19(6):e0302663. PubMed ID: 38833640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time course of methotrexate polyglutamate formation and degradation in the pre-B-leukaemia cell line Nalm6 and in lymphoblasts from children with leukaemia.
    Buchholz B; Frei E; Eisenbarth J; Weigand M; Ludwig R
    Eur J Cancer; 1996 Nov; 32A(12):2101-7. PubMed ID: 9014752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of the Polymorphism of Folylpolyglutamate Synthetase on Treatment of High-Dose Methotrexate in Pediatric Patients with Acute Lymphocytic Leukemia.
    Huang Z; Tong HF; Li Y; Qian JC; Wang JX; Wang Z; Ruan JC
    Med Sci Monit; 2016 Dec; 22():4967-4973. PubMed ID: 27987364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.